[What strategy should be adopted for the screening of uterine cervix adenocarcinoma? ].
Bourgain
Claire
C
Unité de cytologie et de gynécopathologie, université Ziekenhuis Brussel, 101, Laarbeeklaan, 1090 Bruxelles, Belgique. Claire.Bourgain@uzbrussel.be
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000473:pathology / Q000821:virology; D000293:Adolescent; D052685:Alphapapillomavirus / Q000145:classification / Q000302:isolation & purification; D014408:Biomarkers, Tumor / Q000032:analysis; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000473:pathology / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis / Q000473:pathology / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000821:virology; D002575:Uterine Cervicitis / Q000175:diagnosis / Q000473:pathology / Q000821:virology; D014626:Vaginal Smears; D055815:Young Adult
D014408:Biomarkers, Tumor